JP2023523130A5 - - Google Patents
Info
- Publication number
- JP2023523130A5 JP2023523130A5 JP2022554565A JP2022554565A JP2023523130A5 JP 2023523130 A5 JP2023523130 A5 JP 2023523130A5 JP 2022554565 A JP2022554565 A JP 2022554565A JP 2022554565 A JP2022554565 A JP 2022554565A JP 2023523130 A5 JP2023523130 A5 JP 2023523130A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- independently
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025078734A JP2025122005A (ja) | 2020-04-30 | 2025-05-09 | Btk阻害因子とe3リガーゼリガンドとのコンジュゲーションによるブルトンチロシンキナーゼ(btk)の分解及び使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/088322 | 2020-04-30 | ||
| CN2020088322 | 2020-04-30 | ||
| CN2021085369 | 2021-04-02 | ||
| CNPCT/CN2021/085369 | 2021-04-02 | ||
| PCT/CN2021/090898 WO2021219070A1 (en) | 2020-04-30 | 2021-04-29 | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025078734A Division JP2025122005A (ja) | 2020-04-30 | 2025-05-09 | Btk阻害因子とe3リガーゼリガンドとのコンジュゲーションによるブルトンチロシンキナーゼ(btk)の分解及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023523130A JP2023523130A (ja) | 2023-06-02 |
| JP2023523130A5 true JP2023523130A5 (cg-RX-API-DMAC7.html) | 2024-05-09 |
| JP7681038B2 JP7681038B2 (ja) | 2025-05-21 |
Family
ID=78374077
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554565A Active JP7681038B2 (ja) | 2020-04-30 | 2021-04-29 | Btk阻害因子とe3リガーゼリガンドとのコンジュゲーションによるブルトンチロシンキナーゼ(btk)の分解及び使用方法 |
| JP2025078734A Pending JP2025122005A (ja) | 2020-04-30 | 2025-05-09 | Btk阻害因子とe3リガーゼリガンドとのコンジュゲーションによるブルトンチロシンキナーゼ(btk)の分解及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025078734A Pending JP2025122005A (ja) | 2020-04-30 | 2025-05-09 | Btk阻害因子とe3リガーゼリガンドとのコンジュゲーションによるブルトンチロシンキナーゼ(btk)の分解及び使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230167118A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4146655A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7681038B2 (cg-RX-API-DMAC7.html) |
| CN (4) | CN116589466B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021264916B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022019014A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3172498A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL297664A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022013407A (cg-RX-API-DMAC7.html) |
| TW (2) | TWI902789B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021219070A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202209962B (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4146655A4 (en) * | 2020-04-30 | 2024-07-31 | BeiGene, Ltd. | DEGRADATION OF BRUTON TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHOD OF USE |
| US20240246977A1 (en) * | 2020-12-31 | 2024-07-25 | Beigene Switzerland Gmbh | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and method of use |
| MX2023012981A (es) * | 2021-05-03 | 2024-01-11 | Nurix Therapeutics Inc | Compuestos para inhibir o degradar proteinas objetivo, composiciones que los comprenden, metodos para su preparacion y metodos para usarlos. |
| US20240287076A1 (en) * | 2021-05-05 | 2024-08-29 | Biogen Ma Inc. | Compounds for targeting degradation of bruton's tyrosine kinase |
| CA3217792A1 (en) | 2021-05-07 | 2022-11-10 | Kymera Therapeutics, Inc | Cdk2 degraders and uses thereof |
| AU2022300033A1 (en) * | 2021-06-21 | 2024-01-18 | Beone Medicines I Gmbh | (r) -glutarimide crbn ligands and methods of use |
| CN119823111B (zh) * | 2021-11-18 | 2026-05-05 | 正大天晴药业集团股份有限公司 | 稠合酰亚胺类衍生物 |
| CN118414336A (zh) * | 2021-12-30 | 2024-07-30 | 百济神州有限公司 | 通过使布鲁顿酪氨酸激酶(btk)抑制剂与e3连接酶配体缀合来降解btk及使用方法 |
| CA3240051A1 (en) * | 2021-12-30 | 2023-07-06 | Beigene Switzerland Gmbh | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use |
| JP7805983B2 (ja) | 2022-03-22 | 2026-01-26 | アッヴィ・インコーポレイテッド | ブルトン型チロシンキナーゼを分解するためのピリミジン |
| WO2024169871A1 (zh) * | 2023-02-17 | 2024-08-22 | 江苏威凯尔医药科技有限公司 | Btk抑制剂及其用途 |
| CN118946561A (zh) * | 2023-03-10 | 2024-11-12 | 标新生物医药科技(上海)有限公司 | 新颖的e3泛素连接酶配体、蛋白降解剂及其应用 |
| CN117126133B (zh) * | 2023-08-14 | 2026-06-30 | 中国海洋大学 | 一种化合物及其用途 |
| WO2025168081A1 (en) * | 2024-02-09 | 2025-08-14 | Beigene (Suzhou) Co., Ltd. | Treating b-cell proliferative disorder with chimeric degradation activating compound |
| CN120623148A (zh) * | 2024-03-11 | 2025-09-12 | 北京深势科技有限公司 | 一种c-Myc降解剂及其制备方法和用途 |
| TW202543648A (zh) * | 2024-04-19 | 2025-11-16 | 瑞士商百濟神州瑞士有限責任公司 | 包含布魯頓氏酪胺酸激酶降解劑之固體形式及其用途 |
| WO2025232885A1 (en) * | 2024-05-10 | 2025-11-13 | Beigene (Suzhou) Co., Ltd. | Preparation method of a bruton's tyrosine kinase degrader thereof |
| TW202610637A (zh) * | 2024-07-10 | 2026-03-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種雜芳基類化合物、其製備方法及其在醫藥上的應用 |
| WO2026021570A1 (en) * | 2024-07-26 | 2026-01-29 | Ascentage Pharma (Suzhou) Co., Ltd. | Btk degrader and use thereof |
| US20260028345A1 (en) | 2024-07-26 | 2026-01-29 | Ascentage Pharma (Suzhou) Co., Ltd. | Btk degrader and use thereof |
| WO2026119195A1 (en) | 2024-12-04 | 2026-06-11 | Beone Pharmaceutical (Suzhou) Co., Ltd. | A pharmaceutical formulation comprising amorphous solid dispersion of bruton's tyrosin kinase degrader |
| WO2026136866A1 (en) | 2024-12-20 | 2026-06-25 | Prelude Therapeutics Incorporated | Kat6 targeting compounds |
| WO2026153355A1 (zh) * | 2025-01-14 | 2026-07-23 | 江苏恒瑞医药股份有限公司 | 一种杂芳基类化合物、其制备方法及其在医药上的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013157021A1 (en) * | 2012-04-20 | 2013-10-24 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| BR112015007513A2 (pt) * | 2012-10-26 | 2017-07-04 | Hoffmann La Roche | inibidores de tirosina quinase de bruton |
| WO2015089327A1 (en) * | 2013-12-11 | 2015-06-18 | Biogen Idec Ma Inc. | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology |
| CN111936501B (zh) * | 2018-03-26 | 2023-09-22 | 诺华股份有限公司 | 布鲁顿酪氨酸激酶降解剂 |
| EP3774804A1 (en) * | 2018-03-26 | 2021-02-17 | Novartis AG | N-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives |
| EP4146655A4 (en) * | 2020-04-30 | 2024-07-31 | BeiGene, Ltd. | DEGRADATION OF BRUTON TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHOD OF USE |
-
2021
- 2021-04-29 EP EP21797070.6A patent/EP4146655A4/en active Pending
- 2021-04-29 CA CA3172498A patent/CA3172498A1/en active Pending
- 2021-04-29 MX MX2022013407A patent/MX2022013407A/es unknown
- 2021-04-29 IL IL297664A patent/IL297664A/en unknown
- 2021-04-29 CN CN202310380645.1A patent/CN116589466B/zh active Active
- 2021-04-29 US US17/919,847 patent/US20230167118A1/en active Pending
- 2021-04-29 AU AU2021264916A patent/AU2021264916B2/en active Active
- 2021-04-29 CN CN202180031447.3A patent/CN115485278A/zh active Pending
- 2021-04-29 JP JP2022554565A patent/JP7681038B2/ja active Active
- 2021-04-29 TW TW110115475A patent/TWI902789B/zh active
- 2021-04-29 BR BR112022019014A patent/BR112022019014A2/pt unknown
- 2021-04-29 CN CN202511130551.4A patent/CN121159541A/zh active Pending
- 2021-04-29 WO PCT/CN2021/090898 patent/WO2021219070A1/en not_active Ceased
- 2021-04-29 TW TW114138480A patent/TW202608884A/zh unknown
- 2021-04-29 CN CN202310380649.XA patent/CN116589467A/zh active Pending
-
2022
- 2022-09-07 ZA ZA2022/09962A patent/ZA202209962B/en unknown
-
2025
- 2025-05-09 JP JP2025078734A patent/JP2025122005A/ja active Pending